TeamDrive
RUS
Victor Stankevich

Victor Stankevich

Founding Partner, CEO

Телефоны:

+7 495 545-39-12

Send message

Viktor Stankevich is a Founding Partner of RMI Partners, a venture capital investment company in the area of innovative biopharmaceutical products.

Viktor has extensive experience of establishing and developing major projects in different sectors of the economy. In 2006-2012 Victor held different management positions at Mobile TeleSystems (MTS), one of Russia’s largest telecommunications companies. At MTS Group he was Director of External Resource Management and Control, and in 2010 was appointed Head of Procurement and a member of the Management Board.

Previously Victor spent more than 10 years (1996-2006) developing ROSNO insurance company. After becoming a leading player on the Russian insurance market, ROSNO was acquired by the world’s largest insurance company Allianz Holding. Victor was promoted from Head of Treasury to Deputy CEO. His “portfolio” of professional experience includes participation in the foundation of the Institute of Design Automation of the USSR Academy of Sciences, where he was in charge of the laboratory of artificial intelligence systems in design automation.

Victor graduated from Moscow Aviation Institute as a radio engineer, and from the Russian Foreign Trade Academy, specialising in international economic relations. Victor acquired an additional degree in 2002 from the Financial University under the Government of the Russian Federation, specialising in economics and finance.

Media Center

  • 20 April 2018

    Start-up pushes for artificial intelligence to support medical diagnostics

    eleMD, a Russian start-up, is developing a software platform that uses artificial intelligence (AI) for cancer diagnostics and prognostication. Over the past few months the start-up has been focused on fine-tuning the platform’s image recognition functionality for cancer diagnostics, and also on making the solution scalable for medical specialists from across disciplines to be able to analyze heterogeneous medical data. 
     

  • 20 April 2018

    Small biotech companies rule in development of microbiome-targeted therapeutics

    According to leading data and analytics company GlobalData, with smaller biotech companies dominating the pipeline for microbiome-targeted therapeutics, large pharma firms, such as Johnson & Johnson, are eager to collaborate with biotech companies and academic labs to further the development of microbiome-targeted therapeutics in immunology.

  • 19 April 2018

    Can CAR-T and gene therapy cures really sustain biopharma? Not for all, analyst says

    Ever since 2012 when Novartis invested in personalized CAR-T cancer treatments being developed at the University of Pennsylvania, analysts have pondered a difficult question: How can pharma companies profit from curing patients?

  • 18 April 2018

    SID & GP: many Russian pharma companies outdo their foreign counterparts

    According to Vladimir Orlov, Deputy Head of the Educational Center for Good Practices, State Institute of Drugs and Good Practices (SID & GP), a federal budgetary institution, the inspections and checks conducted in major foreign pharmaceutical companies have a great importance for the development of Russian drug manufacturing industry.

Read more